Oxcarbazepine

證據等級: L5

預測適應症: 10 個

Oxcarbazepine: From Focal Epilepsy to Visual Epilepsy

One-Sentence Summary

Oxcarbazepine is an established antiepileptic drug used for focal (partial-onset) seizures. The TxGNN model predicts it may also be effective for Visual Epilepsy (a photosensitive/reflex epilepsy subtype), with 1 clinical trial and 19 publications currently identified in this evidence pack — though most of this literature addresses oxcarbazepine in epilepsy generally rather than the visual subtype specifically.

Quick Overview

Item	Content
Original Indication	Focal (partial-onset) seizures — well-established clinical use; specific TFDA/TGA-approved indication text is not available in this evidence pack
Predicted New Indication	Visual Epilepsy
TxGNN Prediction Score	99.95%
Evidence Level	L2
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, oxcarbazepine is the keto-analogue of carbamazepine and acts primarily as a voltage-gated sodium-channel blocker, stabilising hyperexcitable neuronal membranes. Its efficacy in focal-onset seizures is well established and forms the basis of its current clinical use.

Visual epilepsy (photosensitive/reflex epilepsy) is, unlike most repurposing candidates, still within the seizure-disorder space rather than an unrelated organ system — so the TxGNN prediction is essentially proposing efficacy in a specific seizure subtype rather than a new disease area entirely. This is a meaningfully different clinical question from “does oxcarbazepine treat epilepsy,” because photosensitive/visually-triggered seizures frequently overlap with generalised or absence epilepsy syndromes, for which sodium-channel blockers such as oxcarbazepine and carbamazepine are known to be able to worsen seizure control rather than improve it.

This is a critical caveat: the mechanistic rationale in this evidence pack explicitly flags that the direction of effect is uncertain and depends on correctly identifying the underlying epilepsy subtype before oxcarbazepine could reasonably be considered for visually-triggered seizures.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00855738	Phase 4	Completed	111	Real-world observational (Liceo) study of new AEDs, including oxcarbazepine, as first-choice bitherapy for focal epilepsy; not specific to visual/photosensitive seizures (relevance grade B)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35429132	2022	RCT (multicentre, open-label)	CNS Neuroscience & Therapeutics	Oxcarbazepine vs levetiracetam monotherapy for newly diagnosed focal epilepsy in China; compared quality of life and mental health outcomes
35380580	2022	Review	JAMA	Overview of antiseizure medications for adults with epilepsy, including treatment goals and adverse-effect minimisation
33334546	2020	Review	Seizure	Current role of carbamazepine and oxcarbazepine among ~30 available AEDs in epilepsy management
39899099	2025	Review	Continuum (Minneap Minn)	Updated overview of antiseizure medications, including pharmacokinetics, indications and modes of use
26844734	2016	Review	Continuum (Minneap Minn)	Individual review of antiepileptic drugs covering spectrum of efficacy and clinical pharmacology
11772334	2002	Review	Expert Opin Pharmacother	Oxcarbazepine efficacy as adjunctive/monotherapy for partial-onset seizures, and in trigeminal neuralgia
1379159	1992	Review	Drugs	Pharmacology and therapeutic potential of oxcarbazepine in epilepsy, trigeminal neuralgia and affective disorders
37092337	2023	Review (Pharmacogenomics)	Pharmacogenomics	Population variation in oxcarbazepine efficacy/safety linked to metabolic enzyme and transporter gene variants
8156978	1994	Mechanistic study	Epilepsia	Original mechanism-of-action study showing oxcarbazepine and its active metabolite limit high-frequency neuronal firing
22091603	2012	Clinical study	Epilepsia	Efficacy, tolerability and pharmacokinetics of oxcarbazepine oral loading in patients with recurrent seizures

Note: none of the identified literature specifically studies visual/photosensitive epilepsy — all relate to oxcarbazepine in epilepsy generally.

Australia Market Information

Oxcarbazepine currently has no registered ARTG entries and is not marketed in Australia according to this evidence pack.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. No key warnings, contraindications, or drug-drug interaction data were available in this evidence pack (TFDA/PI warning data is flagged as a blocking data gap, DG001).

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence level is L2, based on a single Phase 4 observational trial that is not specific to visual epilepsy, plus general epilepsy literature. More importantly, the mechanistic rationale itself raises a directional red flag: sodium-channel blockers can worsen generalised/absence-type epilepsy, which frequently overlaps with photosensitive seizure presentations — so efficacy versus harm cannot yet be determined without subtype clarification.

To proceed, the following is needed:

TFDA/TGA Product Information, including warnings and contraindications (currently a blocking data gap)
Confirmed mechanism of action data specific to seizure subtype response
Clinical evidence (trials or case series) directly addressing photosensitive/visually-triggered seizures, distinguishing focal from generalised/absence epilepsy populations
Drug interaction data, given known enzyme-inducing/inhibiting properties of related agents
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.